May 22, 2019

Neil Kumar, Ph.D.
Chief Executive Officer
BridgeBio Pharma LLC
421 Kipling Street
Palo Alto, CA 94301

       Re: BridgeBio Pharma LLC
           Amendment No. 1 to Draft Registration Statement on Form S-1
           Submitted on May 16, 2019
           CIK No. 0001743881

Dear Dr. Kumar:

      We have reviewed your amended draft registration statement and have the
following
comments. In some of our comments, we may ask you to provide us with
information so we
may better understand your disclosure.

       Please respond to this letter by providing the requested information and
either submitting
an amended draft registration statement or publicly filing your registration
statement on
EDGAR. If you do not believe our comments apply to your facts and circumstances
or do not
believe an amendment is appropriate, please tell us why in your response.

      After reviewing the information you provide in response to these comments
and your
amended draft registration statement or filed registration statement, we may
have additional
comments.

Amendment No.1 to Draft Registration Statement on Form S-1 submitted May 16,
2019

Prospectus Summary
Our Platform, page 2

1.     We note your response to comment 1, which we reissue. You continue to
state that you
       only pursue programs with treatment modalities that have been
"validated" in other
       approved products, which implies that you are able to successfully
mitigate development
       risk. Please remove this disclosure here and on pages 117 and 121.
 Neil Kumar, Ph.D.
BridgeBio Pharma LLC
May 22, 2019
Page 2

       You may contact Rolf Sundwall at 202-551-3105 or Mary Mast at
202-551-3613 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Christine Westbrook at 202-551-5019 or Erin Jaskot at 202-551-3442 with
any other
questions.



                                                        Sincerely,
FirstName LastNameNeil Kumar, Ph.D.
                                                        Division of Corporation
Finance
Comapany NameBridgeBio Pharma LLC
                                                        Office of Healthcare &
Insurance
May 22, 2019 Page 2
cc:       Maggie Wong, Esq.
FirstName LastName